{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-114315","form_type":"8-K","ticker":null,"cik":"0001394319","company_name":"Tracon Pharmaceuticals, Inc.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.332589+00:00","generated_at":"2026-05-30T15:17:13.401181+00:00","sec_items":["3.02","5.03","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TRACON fails to achieve quorum for liquidation vote; adjourns special meeting to Nov 12","bullets":["Special meeting to vote on dissolution had only 294,397 shares present; quorum not met.","CEO Craig R. Jalbert acquired a single Super-Voting Share for $0.01, with extra votes only on dissolution.","Bylaws amended: quorum now requires majority of voting power, not majority of outstanding shares.","Super-Voting Share cannot be transferred without board consent; ranks senior to common on liquidation.","Adjourned special meeting scheduled for November 12, 2024 to achieve quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-114315","json":"https://secwatch.observer/filing/0000950170-24-114315.json","markdown":"https://secwatch.observer/filing/0000950170-24-114315.md","text":"https://secwatch.observer/filing/0000950170-24-114315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024114315/0000950170-24-114315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024114315/tcon-20241011.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:17:13.401181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"865846b16de718f7ec14f298e9606b9d5d4534fe","claim":"Tracon Pharmaceuticals, Inc.: Filed Certificate of Designation of Series A Preferred Stock to establish a super-voting share with specific rights and preferences (effective 2024-10-11).","evidence_excerpt":"On October 11, 2024, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware with respect to the Super-Voting Share.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024114315/0000950170-24-114315-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-10-11"}],"fact_type":"governance_change"},{"claim_id":"f95b80f3b0f2f98488e32354396a0b1dd1053e2d","claim":"Tracon Pharmaceuticals, Inc.: Amended Article III, Section 8 of the bylaws to allow holders of a majority of voting power (rather than a majority of outstanding shares) to constitute a quorum (effective 2024-10-11).","evidence_excerpt":"On October 11, 2024, the Board approved the amendment of Article III, Section 8 of the Company’s bylaws to enable the holders of a majority of the voting power of, rather than the majority of, the outstanding shares of stock of the Company entitled to vote at a meeting of stockholders to constitute a quorum for the transaction of business.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024114315/0000950170-24-114315-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-10-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}